ClinicalTrials.gg
CompletedNCT05552508BURANUpdated Mar 25, 2025Results posted

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

A Phase 4 interventional study of Benralizumab in Asthma, sponsored by AstraZeneca. Completed at 25 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
29th of 39
45 · median 128
Started
2022
the only one that year
Phase 4
9 of 39
2 open now
Registered
34th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 29th largest by enrollment, is the only one that started in 2022, is one of 9 in phase 4, and was the 34th registered.

Asthma

4,846 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.

Read the detailed description

This is a phase IV, interventional single group, open-label, uncontrolled, prospective, multicenter clinical trial.

This study will be conducted in male and female participants ≥18 years old with established severe eosinophilic asthma as defined by European Respiratory Society (ERS)/American Thoracic Society (ATS) clinical guidelines inadequately controlled by treatment with Inhaled Corticosteroids-Long-acting β2 agonists (ICS-LABA) with or without oral corticosteroids (OCS) or other asthma controller medications.

Each participant will participate in the study for a minimum of 15 weeks and up to 23 weeks.

This study will comprise of:

Screening visit (V0) Visit 1 (V1; week 0; within 1 to 21 days of screening) Visit 2 (V2; week 4 ± 5 days) Visit 3 (V3; week 8 ± 5 days) Visit 4 (V4; week 13 ± 5 days) Follow-up (2 weeks [± 7 days] after V4) - Phone call follow-up. Participants will be discharged from the study after the phone call follow-up is completed.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • BURAN
  • Inhaled Corticosteroids
  • Long-acting β2 agonists
  • Benralizumab
  • Eosinophilic Asthma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are diagnosed with asthma with documented reversibility post-bronchodilator or salbutamol either historical or at Visit 0 (V0).
  • Participants who have documented treatment with ICS and LABA for ≥ 3 months prior to V0 with or without oral and additional asthma controllers.
  • Participants who have documented peripheral blood eosinophil count ≥ 300 cells/μL at V0, or if Oral Corticosteroids (OCS)-dependent, a documented peripheral blood eosinophil count ≥ 150 cells/μL at V0.
  • Participants who have had a minimum of 2 exacerbations in the last 12 months prior to V0.
  • Participants who have pre-bronchodilator (FEV1)/Forced Vital Capacity (FVC) ≤ 70% at Visit 0 (V0).
  • Participants who have pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) \< 80% of predicted at V0.
  • Participants who can perform acceptable and repeatable spirometry.
  • Participants who can withhold asthma maintenance medication for at least 12 hours prior to V0, 1 and 4 where spirometry and/or Computed Tomography (CT) scan procedures will be performed except for once-a-day dosage where 24 hours will be required.
  • Female participants who have a negative pregnancy test prior to administration of the product (IP) and high-resolution CT scan and must agree to use a highly effective method of from randomization throughout the study duration and within 12 weeks after last dose of IP.

Exclusion criteria

Exclusion Criteria:

  • Participants who are unstable or who experienced an exacerbation/infection in the 6 weeks before V0.
  • Participants with acute upper or lower airway infection in the 6 weeks before V0.
  • Participants diagnosed with pulmonary disease other than asthma, or participants who have ever been diagnosed with pulmonary or systemic disease, other than asthma that are associated with elevated peripheral eosinophil count.
  • Receipt of any biologic products for asthma within 4 months or 5 half-lives prior to V0 whichever is longer.
  • History or current use of chronic (i.e., > 4 weeks) medication.
  • History of lung volume reduction surgery, lung resection, thermal bronchoplasty at any time before visit 0 (V0) or on active phase of pulmonary rehabilitation.
  • Participants with current or history of malignancy.
  • History of other clinically significant disease or abnormality.
  • Participants with positive , C or .
  • Participants with:

Positive COVID-19 test at V0, COVID-19 disease within 6 weeks before V0 or History of severe COVID-19 disease at any time, defined by the need for Intensive Care Unit stay or Mechanical Ventilation (invasive or non-invasive).

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Participants will receive 3 doses of benralizumab having a strength of 30 mg subcutaneously once every 4 weeks (Week 0, Week 4, and Week 8).

    Combination Product: Benralizumab

Interventions

  • Combination productBenralizumab

    Participants will receive benralizumab subcutaneously.

    Also known as: Fasenra

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Untrimmed Total Mucus Volume at TLC

    Change from baseline in airway dynamics after 13 weeks following treatment with benralizumab, using total mucus volume (specific airway volume) at total lung capacity (TLC) measurements from untrimmed airways was assessed.

    Time frame: Baseline and Week 13

Secondary outcomes

  1. Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC

    Change from baseline in untrimmed total mucus plugs score at TLC was assessed. Mucus plugs was scored with a scoring system similar to that by Dunican et al. with the Severe Asthma Research Program (SARP) based on bronchopulmonary segmental anatomy. The mucus score was calculated by counting the number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of the airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug\[s\] present) or 0 (mucus plug\[s\] absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores indicate worse outcome.

    Time frame: Baseline and Week 13

  2. Change From Baseline in Untrimmed Total Air Trapping at FRC

    Change from baseline in untrimmed total air trapping at FRC was assessed.

    Time frame: Baseline and Week 13

  3. Change From Baseline in Trimmed Distal Airway Wall Volume at TLC

    Change from baseline in trimmed distal airway wall volume at TLC was assessed. Change from baseline in airway dynamics at Week 13 following treatment with benralizumab as measured by secondary FRI endpoints, irrespective of participants characteristics was assessed.

    Time frame: Baseline and Week 13

  4. Change From Baseline in Untrimmed Distal Airway Volume at TLC

    Change from baseline in untrimmed distal airway volume at TLC was assessed.

    Time frame: Baseline and Week 13

  5. Change From Baseline in Untrimmed Distal Airway Volume at Functional Residual Capacity (FRC)

    Change from baseline in untrimmed distal airway volume at FRC was assessed.

    Time frame: Baseline and Week 13

  6. Change From Baseline in Untrimmed Total Lung Volume at TLC

    Change from baseline in untrimmed total lung volume at TLC was assessed.

    Time frame: Baseline and Week 13

  7. Change From Baseline in Untrimmed Total Lung Volume at FRC

    Change from baseline in untrimmed total lung volume at FRC was assessed.

    Time frame: Baseline and Week 13

  8. Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% confidence interval (CI) for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  9. Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FEV1

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  10. Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FEV1

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  11. Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FEV1

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  12. Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FEV1

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  13. Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FEV1

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  14. Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FEV1

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  15. Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FEV1

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  16. Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Vital Capacity (Pre-BD FVC)

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  17. Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FVC

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  18. Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FVC

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  19. Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FVC

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  20. Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FVC

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  21. Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FVC

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  22. Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FVC

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  23. Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FVC

    The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

    Time frame: At Baseline (Week 0)

  24. Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FEV1

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

    Time frame: Baseline and Week 13

  25. Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FEV1

    Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.

    Time frame: Baseline and Week 13

  26. Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FEV1

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

    Time frame: Baseline and Week 13

  27. Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FEV1

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

    Time frame: Baseline and Week 13

  28. Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FEV1

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

    Time frame: Baseline and Week 13

  29. Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FEV1

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

    Time frame: Baseline and Week 13

  30. Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FVC

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

    Time frame: Baseline and Week 13

  31. Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FVC

    Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.

    Time frame: Baseline and Week 13

  32. Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FVC

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

    Time frame: Baseline and Week 13

  33. Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FVC

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

    Time frame: Baseline and Week 13

  34. Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FVC

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

    Time frame: Baseline and Week 13

  35. Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FVC

    The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

    Time frame: Baseline and Week 13

  36. Number of Participants With Adverse Events (AEs)

    The safety and tolerability of benralizumab was assessed.

    Time frame: From screening (Day -21) to follow-up (up to 1.9 years)

07

Results

Posted Mar 25, 2025

Participant flow

This study was conducted between 11 October 2022 to 19 July 2024 at 24 study centers in in Australia, Belgium, France, Portugal, Spain, United Kingdom, and United States.

Participant flow — Overall Study
MilestoneBenralizumab
Started45
Completed42
Not completed3
Withdrew: Adverse event3

Outcome measures

PrimaryChange From Baseline in Untrimmed Total Mucus Volume at TLC

Change from baseline in airway dynamics after 13 weeks following treatment with benralizumab, using total mucus volume (specific airway volume) at total lung capacity (TLC) measurements from untrimmed airways was assessed.

Time frame:
Baseline and Week 13
Reported as:
Mean · Milliliters (mL)
Change From Baseline in Untrimmed Total Mucus Volume at TLC
Milliliters (mL)Benralizumab
All participants-0.1279 ± 0.4199
Participants with >=4 mucus plugs-0.1822 ± 0.4977
Participants with <4 mucus plugs-0.0056 ± 0.0111
OCS-dependent participants-0.1619 ± 0.4627
Non-OCS-dependent participants-0.1260 ± 0.4244
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.0327
  • Benralizumab · t-test, 2 sided · p = 0.0359
  • Benralizumab · t-test, 2 sided · p = 0.1088
  • Benralizumab · t-test, 2 sided · p = 0.0391
SecondaryChange From Baseline in Untrimmed Total Mucus Plugs Score at TLC

Change from baseline in untrimmed total mucus plugs score at TLC was assessed. Mucus plugs was scored with a scoring system similar to that by Dunican et al. with the Severe Asthma Research Program (SARP) based on bronchopulmonary segmental anatomy. The mucus score was calculated by counting the number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of the airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug\[s\] present) or 0 (mucus plug\[s\] absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores indicate worse outcome.

Time frame:
Baseline and Week 13
Reported as:
Mean · Scores on a scale
Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC
Scores on a scaleBenralizumab
Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC-11.0 ± 32.8
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.0423
SecondaryChange From Baseline in Untrimmed Total Air Trapping at FRC

Change from baseline in untrimmed total air trapping at FRC was assessed.

Time frame:
Baseline and Week 13
Reported as:
Mean · Percentage of air trapping
Change From Baseline in Untrimmed Total Air Trapping at FRC
Percentage of air trappingBenralizumab
Change From Baseline in Untrimmed Total Air Trapping at FRC-0.1410 ± 12.1660
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.9465
SecondaryChange From Baseline in Trimmed Distal Airway Wall Volume at TLC

Change from baseline in trimmed distal airway wall volume at TLC was assessed. Change from baseline in airway dynamics at Week 13 following treatment with benralizumab as measured by secondary FRI endpoints, irrespective of participants characteristics was assessed.

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Trimmed Distal Airway Wall Volume at TLC
mLBenralizumab
Change From Baseline in Trimmed Distal Airway Wall Volume at TLC-0.9386 ± 6.1359
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.3455
SecondaryChange From Baseline in Untrimmed Distal Airway Volume at TLC

Change from baseline in untrimmed distal airway volume at TLC was assessed.

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Untrimmed Distal Airway Volume at TLC
mLBenralizumab
Change From Baseline in Untrimmed Distal Airway Volume at TLC1.1225 ± 4.5836
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.2484
SecondaryChange From Baseline in Untrimmed Distal Airway Volume at Functional Residual Capacity (FRC)

Change from baseline in untrimmed distal airway volume at FRC was assessed.

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Untrimmed Distal Airway Volume at Functional Residual Capacity (FRC)
mLBenralizumab
Change From Baseline in Untrimmed Distal Airway Volume at Functional Residual Capacity (FRC)0.5079 ± 1.9741
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.9405
SecondaryChange From Baseline in Untrimmed Total Lung Volume at TLC

Change from baseline in untrimmed total lung volume at TLC was assessed.

Time frame:
Baseline and Week 13
Reported as:
Mean · Liters (L)
Change From Baseline in Untrimmed Total Lung Volume at TLC
Liters (L)Benralizumab
Change From Baseline in Untrimmed Total Lung Volume at TLC0.0287 ± 0.4416
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.6867
SecondaryChange From Baseline in Untrimmed Total Lung Volume at FRC

Change from baseline in untrimmed total lung volume at FRC was assessed.

Time frame:
Baseline and Week 13
Reported as:
Mean · Liters (L)
Change From Baseline in Untrimmed Total Lung Volume at FRC
Liters (L)Benralizumab
Change From Baseline in Untrimmed Total Lung Volume at FRC-0.0275 ± 0.5101
Statistical analysis
  • Benralizumab · t-test, 2 sided · p = 0.7554
SecondaryCorrelation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1)

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% confidence interval (CI) for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1)
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1)-0.2710 (-0.5260 to 0.0352)
SecondaryCorrelation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FEV1

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FEV1
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FEV1-0.2795 (-0.5326 to 0.0260)
SecondaryCorrelation Between Untrimmed Total Air Trapping at FRC and Pre-BD FEV1

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FEV1
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FEV1-0.6892 (-0.8210 to -0.4742)
SecondaryCorrelation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FEV1

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FEV1
Correlation coefficientBenralizumab
Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FEV10.5380 (0.2738 to 0.7205)
SecondaryCorrelation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FEV1

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FEV1
Correlation coefficientBenralizumab
Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FEV10.6556 (0.4360 to 0.7958)
SecondaryCorrelation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FEV1

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FEV1
Correlation coefficientBenralizumab
Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FEV10.4357 (0.1383 to 0.6548)
SecondaryCorrelation Between Untrimmed Total Lung Volume at TLC and Pre-BD FEV1

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FEV1
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FEV10.2122 (-0.0966 to 0.4799)
SecondaryCorrelation Between Untrimmed Total Lung Volume at FRC and Pre-BD FEV1

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FEV1
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FEV1-0.1655 (-0.4519 to 0.1560)
SecondaryCorrelation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Vital Capacity (Pre-BD FVC)

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Vital Capacity (Pre-BD FVC)
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Mucus Volume Measured at TLC and Pre-bronchodilator Forced Vital Capacity (Pre-BD FVC)-0.0471 (-0.3421 to 0.2574)
SecondaryCorrelation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FVC

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FVC
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Mucus Plugs Score at TLC and Pre-BD FVC-0.0273 (-0.3247 to 0.2756)
SecondaryCorrelation Between Untrimmed Total Air Trapping at FRC and Pre-BD FVC

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FVC
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Air Trapping at FRC and Pre-BD FVC-0.3432 (-0.5886 to -0.0311)
SecondaryCorrelation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FVC

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FVC
Correlation coefficientBenralizumab
Correlation Between Trimmed Distal Airway Wall Volume at TLC and Pre-BD FVC0.5476 (0.2863 to 0.7269)
SecondaryCorrelation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FVC

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FVC
Correlation coefficientBenralizumab
Correlation Between Untrimmed Distal Airway Volume at TLC and Pre-BD FVC0.6110 (0.3742 to 0.7670)
SecondaryCorrelation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FVC

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FVC
Correlation coefficientBenralizumab
Correlation Between Untrimmed Distal Airway Volume at FRC and Pre-BD FVC0.4706 (0.1806 to 0.6789)
SecondaryCorrelation Between Untrimmed Total Lung Volume at TLC and Pre-BD FVC

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FVC
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Lung Volume at TLC and Pre-BD FVC0.4947 (0.2227 to 0.6891)
SecondaryCorrelation Between Untrimmed Total Lung Volume at FRC and Pre-BD FVC

The relationship between airway dynamics and conventional lung function measurements, cross sectionally (at week 0) and irrespective of participants characteristics was assessed. Positive correlations were identified by values greater than 0, and negative correlations were identified by values less than 0. Statistical significance is indicated when the lower limit of the 95% CI for the correlation is greater than 0 for positive correlations or less than 0 for negative correlations. Here, "Number" in measure type is indicating data of Spearman's rank correlation coefficient.

Time frame:
At Baseline (Week 0)
Reported as:
Number · Correlation coefficient
Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FVC
Correlation coefficientBenralizumab
Correlation Between Untrimmed Total Lung Volume at FRC and Pre-BD FVC0.1451 (-0.1761 to 0.4354)
SecondaryChange From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FEV1

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FEV1
mLBenralizumab
No adjustment for pre-BD FEV10.05 (0.00 to 0.11)
Adjusted for pre-BD FEV10.06 (0.00 to 0.12)
SecondaryChange From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FEV1

Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.

Time frame:
Baseline and Week 13
Reported as:
Mean · Scores on a scale
Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FEV1
Scores on a scaleBenralizumab
No adjustment for pre-BD FEV14.38 (-2.87 to 11.63)
Adjusted for pre-BD FEV15.97 (-1.75 to 13.69)
SecondaryChange From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FEV1

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

Time frame:
Baseline and Week 13
Reported as:
Mean · Percentage of air trapping
Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FEV1
Percentage of air trappingBenralizumab
No adjustment for pre-BD FEV13.18 (-3.65 to 10.01)
Adjusted for pre-BD FEV15.24 (-1.23 to 11.71)
SecondaryChange From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FEV1

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FEV1
mLBenralizumab
No adjustment for pre-BD FEV15.29 (-1.39 to 11.97)
Adjusted for pre-BD FEV15.61 (-1.27 to 12.48)
SecondaryChange From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FEV1

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FEV1
mLBenralizumab
Untrimmed distal airway volume at TLC: No adjustment for pre-BD FEV12.20 (-1.09 to 5.49)
Untrimmed distal airway volume at TLC: Adjusted for pre-BD FEV10.61 (-2.65 to 3.88)
Untrimmed distal airway volume at FRC: No adjustment for pre-BD FEV1-1.28 (-2.82 to 0.27)
Untrimmed distal airway volume at FRC: Adjusted for pre-BD FEV1-1.52 (-3.14 to 0.09)
SecondaryChange From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FEV1

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FEV1).

Time frame:
Baseline and Week 13
Reported as:
Mean · Litre
Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FEV1
LitreBenralizumab
Untrimmed total lung volume at TLC: No adjustment for pre-BD FEV10.11 (-0.62 to 0.84)
Untrimmed total lung volume at TLC: Adjusted for pre-BD FEV10.13 (-0.61 to 0.88)
Untrimmed total lung volume at FRC: No adjustment for pre-BD FEV10.52 (-0.16 to 1.21)
Untrimmed total lung volume at FRC: Adjusted for pre-BD FEV10.37 (-0.25 to 0.99)
SecondaryChange From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FVC

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Untrimmed Total Mucus Volume Measured at TLC With and Without Adjustment for Pre-BD FVC
mLBenralizumab
No adjustment for pre-BD FVC0.05 (0.00 to 0.11)
Adjusted for pre-BD FVC0.05 (-0.01 to 0.11)
SecondaryChange From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FVC

Relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC). Mucus plugs was scored with a scoring system similar to that by Dunican et al. with SARP based on bronchopulmonary segmental anatomy. Mucus score was calculated by counting number of bronchopulmonary segments which contained 1 or more mucus plug, up to a maximum score of 18 corresponding to the 18 bronchopulmonary segments present in most people. In this system, a mucus plug is defined as a complete occlusion of airway visible at TLC. Each bronchopulmonary segment is given a score of 1 (mucus plug present) or 0 (mucus plug absent). The segment scores of each lobe are summed to generate a total mucus score for both lungs, yielding a mucus score ranging from 0-18. Higher scores = worse outcome.

Time frame:
Baseline and Week 13
Reported as:
Mean · Scores on a scale
Change From Baseline in Untrimmed Total Mucus Plugs Score at TLC With and Without Adjustment for Pre-BD FVC
Scores on a scaleBenralizumab
No adjustment for pre-BD FVC4.38 (-2.87 to 11.63)
Adjusted for pre-BD FVC4.65 (-3.00 to 12.30)
SecondaryChange From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FVC

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at Week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

Time frame:
Baseline and Week 13
Reported as:
Mean · Percentage of air trapping
Change From Baseline in Untrimmed Total Air Trapping at FRC With and Without Adjustment for Pre-BD FVC
Percentage of air trappingBenralizumab
No adjustment for pre-BD FVC3.18 (-3.65 to 10.01)
Adjusted for pre-BD FVC4.36 (-2.06 to 10.79)
SecondaryChange From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FVC

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Trimmed Distal Airway Wall Volume at TLC With and Without Adjustment for Pre-BD FVC
mLBenralizumab
No adjustment for pre-BD FVC5.29 (-1.39 to 11.97)
Adjusted for pre-BD FVC6.08 (-0.60 to 12.76)
SecondaryChange From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FVC

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

Time frame:
Baseline and Week 13
Reported as:
Mean · mL
Change From Baseline in Untrimmed Distal Airway Volume With and Without Adjustment for Pre-BD FVC
mLBenralizumab
Untrimmed distal airway volume at TLC: No adjustment for pre-BD FVC2.20 (-1.09 to 5.49)
Untrimmed distal airway volume at TLC: Adjusted for pre-BD FVC1.22 (-2.30 to 4.73)
Untrimmed distal airway volume at FRC: No adjustment for pre-BD FVC-1.28 (-2.82 to 0.27)
Untrimmed distal airway volume at FRC: Adjusted for pre-BD FVC-1.28 (-2.93 to 0.37)
SecondaryChange From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FVC

The relationship between changes from baseline (week 0) in airway dynamics and conventional lung function measurements at week 13, after accounting for baseline measurements of conventional lung function was assessed with and without adjustment for conventional lung function measures (pre-BD FVC).

Time frame:
Baseline and Week 13
Reported as:
Mean · Litre
Change From Baseline in Untrimmed Total Lung Volume With and Without Adjustment for Pre-BD FVC
LitreBenralizumab
Untrimmed total lung volume at TLC: No adjustment for pre-BD FVC0.11 (-0.62 to 0.84)
Untrimmed total lung volume at TLC: Adjusted for pre-BD FVC0.11 (-0.63 to 0.85)
Untrimmed total lung volume at FRC: No adjustment for pre-BD FVC0.52 (-0.16 to 1.21)
Untrimmed total lung volume at FRC: Adjusted for pre-BD FVC0.40 (-0.22 to 1.02)
SecondaryNumber of Participants With Adverse Events (AEs)

The safety and tolerability of benralizumab was assessed.

Time frame:
From screening (Day -21) to follow-up (up to 1.9 years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsBenralizumab
Any AE17
Any serious adverse event (SAE)2
Any SAE with outcome death0
Any AE leading to discontinuation of study intervention1
Any possibly related AE3

Adverse events

Collected over From screening (Day -21) to follow-up (up to 1.9 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab0/45 (0%)2/45 (4.4%)3/45 (6.7%)
Most frequent serious events
Most frequent serious events
EventBenralizumab
Respiratory tract infectionInfections and infestations1/45
AsthmaRespiratory, thoracic and mediastinal disorders1/45
Most frequent other events
Most frequent other events
EventBenralizumab
GastroenteritisInfections and infestations3/45

Baseline characteristics

Primary analysis population set consisted portion of the evaluable population that did not have any acute asthma exacerbation nor lower respiratory tract infection during the study period.

Age, Continuous
Age, Continuous(Years)Benralizumab
Mean54.5 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab
Female23
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Benralizumab
Hispanic or Latino6
Not Hispanic or Latino33
Unknown or Not Reported0
08

Study locations

25 sites
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Loxahatchee Groves, Florida 33470, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Greenwood, Indiana 46143, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    DuBois, Pennsylvania 15801, United States
  • Research Site
    Tyler, Texas 75708, United States
  • Research Site
    Webster, Texas 77598, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Toorak Gardens, 5065, Australia
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Namur, 5101, Belgium
  • Research Site
    Montpellier Cedex 5, 34295, France
  • Research Site
    Lisboa, 1649-035, Portugal
  • Research Site
    Porto, 4100-180, Portugal
  • Research Site
    Barcelona, 08006, Spain
  • Research Site
    Barcelona, 08017, Spain
  • Research Site
    Barcelona, 8003, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Villarreal (Castellón), 12540, Spain
  • Research Site
    Bradford, BND9 6RJ, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jul 2024, 21 months.

Results were first posted in Mar 2025, 8 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 21 months is close to that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
Sep 23, 2022
StartActual
Oct 11, 2022
Primary completionActual
Jul 19, 2024
CompletionActual
Jul 19, 2024
Results first posted
Mar 25, 2025
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05552508
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Oct 11, 2022
Primary completion
Jul 19, 2024
Completion
Jul 19, 2024
Results posted
Mar 25, 2025
Last update
Mar 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion